According to The Insight Partners' research, the Europe Vaccines Market was valued at US$ 24,528.3 Million in 2024 and is expected to reach US$ 35,815.1 Million by 2031, registering a CAGR of 5.6% from 2025 to 2031.
Integration of Artificial Intelligence & Big Data in vaccine development and development of combination and therapeutic vaccines are among the critical factors attributed to drive the Europe vaccines market growth.
Artificial intelligence (AI) and machine learning are reshaping the landscape of vaccine research and development by introducing innovative methodologies that enhance speed and accuracy. One of the most critical applications of AI is in the analysis of complex genomic and immunological data. This technology enables researchers to rapidly identify potential vaccine targets by sifting through vast amounts of data- a process that would have traditionally taken years to accomplish. The ability to predict immune responses to these targets is particularly revolutionary, providing insights to design vaccines in a much shorter timeframe.
The strategic value of artificial intelligence (AI) was evident during the COVID-19 pandemic, where it played a critical role in accelerating mRNA vaccine development clinical trials timelines-enabling companies to move from viral genome sequencing to regulatory approval within a year.
In the manufacturing arena, the implementation of AI significantly enhances production efficiency. AI systems can streamline various stages of the production process, enhance quality control by monitoring and identifying deviations from expected standards, and forecast potential bottlenecks that could delay vaccine delivery. This proactive approach not only speeds up the production timeline but also ensures that vaccines are manufactured with a higher degree of reliability. In October 2025, Denmark company Evaxion Biotech announced the launch of a module for automated vaccine design, as an addition to its AI-Immunology platform, which increases its ability to apply artificial intelligence to discover and improve vaccine candidates. This technology significantly reduces the time and resources for vaccine development by automating manual processes and can potentially apply to either the creation of a new vaccine or improvement of existing vaccines. Evaxion was present to share its advancements at the World Vaccine Congress Europe held in Amsterdam. This technology represents a clear example of the opportunity that Europe has to be at the forefront of AI vaccine development. Overall, the integration of AI and machine learning into vaccine development processes is making this critical field more efficient, scalable, and adaptable to the rapidly evolving landscape of global health threats, ultimately contributing to more effective public health responses.
On the contrary, high vaccine development cost and increased time to market hampers the growth of the Europe vaccines market.
Europe Vaccines Market Segmentation Analysis:
- By Type, the Europe Vaccines Market is segmented into Conjugated Vaccines, Inactivated Vaccines, Live Vaccines, Recombinant Vaccines, and Toxoid Vaccines. The Conjugated segment is projected to expand at a CAGR of 6.2% during 2025 - 2031.
- By Indication, the Europe Vaccines Market is segmented into HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Other. The HPV segment is projected to expand at a CAGR of 7.3% during 2025 - 2031.
- By Route Of Administration, the Europe Vaccines Market is segmented into Injection, Oral, and Other. The Injection segment is projected to expand at a CAGR of 5.3% during 2025 - 2031.
- By Age Group, the Europe Vaccines Market is segmented into Pediatric and Adult. The Pediatric segment is projected to expand at a CAGR of 5.7% during 2025 - 2031.
By country, the Europe Vaccines Market is categorized into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. Germany is projected to expand at a CAGR of 6.4% during 2025 - 2031.
Key players operating in the Vaccines Market are Abbott Laboratories, GSK Plc, Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, CSL Ltd, Serum Institute of India Pvt Ltd, BioNTech SE, and Sinovac Biotech Ltd., among others.
In June 2025, Valneva SE partnered with CSL Limited to improve vaccine sales in Germany. Analysts predict a strong increase in Valneva SE stock value. According to GuruFocus, the stock could have a fair value increase of about 40% in the next year.
In January 2025, Primrose Bio, Inc. and Serum Institute of India Pvt. Ltd. partnered to create a new multi-antigen vaccine for widespread infections. Primrose will handle the design and manufacturing of strains using their technology, while SIIPL will focus on further development and selling the vaccine.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com